Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436199 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
A Phase 3 study, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT03436199: Completed Phase 3 study, sponsored by Adamas Pharmaceuticals.
NCT03436199 is a Phase 3 study that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 558 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03436199, a Phase 3 study, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
Primary Outcome
The T25FW is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. For this outcome measure, the result is reported as speed (feet per second). Improvement is indicated by an increase in speed.
Interventions
- OTHER Placebo
- DRUG ADS-5102, 274 mg
- DRUG ADS-5102, 137 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 3 |
What the finished NCT03436199 record still lists
NCT03436199 is an interventional study that assigns participants to a tested intervention. The registered 558 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03436199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03436199 about?
NCT03436199 is a clinical study titled "Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment". This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
What is the current status of trial NCT03436199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2018-03-29. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT03436199?
The interventions under investigation include: Placebo (OTHER), ADS-5102, 274 mg (DRUG), ADS-5102, 137 mg (DRUG).
Who is sponsoring clinical trial NCT03436199?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03436199's enrollment target sits among peer trials
558 673rd of 2000 higher than 1,327 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07173751 · 558 participants · Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI